Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: A double-blind, randomised, multicentre trial

Lancet

Volumn 353, Issue 9149, 1999, Pages 259-266

  Smolen, Josef S ^a,b   Kalden, Joachim R ^c   Scott, David L ^d   Rozman, Blaz ^h   Kvien, Tore K ^e   Larsen, Arvi ^f   Loew Friedrich, Iris ^g   Oed, Christine ^g   Rosenburg, Ronald ^g  

^a UNIVERSITY OF VIENNA   (Austria)

^b GENERAL HOSPITAL LINZ   (Austria)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d KING S COLLEGE HOSPITAL   (United Kingdom)

^e DIAKONHJEMMET HOSPITAL   (Norway)

^f NORWEGIAN KNOWLEDGE CENTRE FOR THE HEALTH SERVICES   (Norway)

^g SANOFI   (France)

^h NONE

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; LEFLUNOMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SALAZOSULFAPYRIDINE;

ADULT; AGRANULOCYTOSIS; ALOPECIA; ARTHRALGIA; ARTICLE; BACKACHE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERTENSION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RESPIRATORY TRACT INFECTION; RHEUMATOID ARTHRITIS;

EID: 0033053835     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)09403-3     Document Type: Article

References (43)

1. Pincus T, Callahan LF What is the natural history of rheumatoid arthritis? Rheum Dis Clin North Am. 19:1993;123-151.
2. van der Heijde DMFM, van Riel PLCM, van Leeuween MAet al. Prognostic factors, radiographic damage and physical disability in early rheumatoid arthritis: a prospective follow-up study of 147 patients. Br J Rheumatol. 31:1992;519-525.
3. Eberhardt JB, Rydgren LC, Petterson Het al. Early rheumatoid arthritis-onset, course, and outcome over 2 years. Rheumatol Int. 10:1990;135-142.
4. Cash JM, Klippel JH Second-line drug therapy for rheumatoid arthritis. N Engl J Med. 330:1994;1369-1375.
5. Ward MM, Fries JF Trends in antirheumatic medication use among patients with rheumatoid arthritis, 1981-1996. J Rheumatol. 25:1998;408-416.
6. Alarcón GS, López-Méndez A, Walter Jet al. Radiographic evidence of disease progression in methotrexate treated and nonmethotrexate disease modifying antirheumatic drug treated rheumatoid arthritis patients: a meta-analysis. J Rheumatol. 19:1992;1868-1873.
7. Forre O Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine: results of a 48-week multicentre study comparing low-dose cyclosporine with placebo. Arthritis Rheum. 37:1994;1506-1512.
8. van der Heijde DMFM, van Riel PLCM, Nuver-Zwart IHet al. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet. i:1989;1036-1038.
9. Neumann VC, Grindulis KA, Hubbal S, McConkey B, Wright V Comparison between penicillamine and sulphasalazine in rheumatoid arthritis: Leeds-Birmingham trial. BMJ. 287:1983;1099-1102.
10. Felson DT, Anderson JJ, Meenan RF Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis: a meta-analysis of published clinical trials. Arthritis Rheum. 35:1992;1117-1125.
11. O'Dell JR, Haire CE, Erikson Net al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med. 334:1996;1287-1291.
12. Boers M, Verhoeven AC, Markusse HMet al. Randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet. 350:1997;309-318.
13. Pincus T, Marcum SB, Callahan LF Long-term drug therapy for rheumatoid arthritis in seven rheumatology private practices: II second-line drugs and prednisone. J Rheumatol. 19:1992;1885-1894.
14. Wolfe F Adverse drug reactions of DMARDs and DC-ARTs in rheumatoid arthritis. Clin Exp Rheumatol. 15(suppl 17):1997;75-81.
15. Bartlett RR, Anagnostopulos H, Zielinski Tet al. Effects of leflunomide on immune responses and models of inflammation. Semin Immunopathol. 14:1993;381-394.
16. Rückermann K, Fairbanks LD, Carrey LAet al. Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T lymphocytes from healthy humans. J Biol Chem. 273:1998;21682-21691.
17. Fox RI Mechanism of action of leflunomide in rheumatoid arthritis. J Rheumatol. 25(suppl 53):1998;20-26.
18. Panayi GS, Lanchbury JS, Kingsley GH The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis. Arthritis Rheum. 35:1992;729-735.
19. Smolen JS, Tohidast Akrad M, Gal Aet al. The role of T-lymphocytes and cytokines in rheumatoid arthritis. Scand J Rheumatol. 25:1996;1-4.
20. Steiner G, Akrad M, Witzmann G, et al Demonstration of T cell derived cytokines in joint diseases: do T cells play a role in the pthophysiology of rheumatoid arthritis? Br J Rheumatol (in press).
21. Bartlett RR, Popovic S, Raiss RX Development of autoimmunity in MRL/lpr mice and the effect of drugs on this murine disease. Scand J Rheumatol. 75(suppl):1988;S290.
22. Mladenovic V, Domljan Z, Rozman Bet al. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Arthritis Rheum. 38:1995;1595-1603.
23. Arnett FC, Edworthy SM, Bloch DAet al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31:1988;315-324.
24. Smolen JS, Breedveld FC, Eberl Get al. Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activity. Arthritis Rheum. 38:1995;38-43.
25. Weber W, Harnisch L Use of a population pharmacokinetic model to predict clinical outcome of leflunomide, a new DMARD in the treatment of rheumatoid arthritis. Arthritis Rheum. 40(suppl):1997;S153.
26. Van Riel PLCM, van Gerstel AM, van de Putte LBA Long-term usage and side-effect profile of sulphasalazine in rheumatoid arthritis. Br J Rheumatol. 34(suppl 2):1995;40-42.
27. Fries JF, Spitz P, Kraines RG, Holman HR Measurement of patient outcome in arthritis. Arthritis Rheum. 23:1980;137-145.
28. Larsen A, Dale K, Eck M Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol. 18:1977;481-491.
29. Larsen A. Radiographic evaluation of rheumatoid arthritis in therapeutic trials. In: Paulus HE, Ehrlich GE, Lindenlaub E, eds. Controversies in the clinical evaluation of analgesic, anti-inflammatory, antirheumatic drugs. Stuttgart: FK Schattauer Verlag, 1981: xxx-xx.
30. Felson DT, Anderson JJ, Boers Met al. The American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis clinical trials. Arthritis Rheum. 38:1995;724-735.
31. Paulus HE, Egger MJ, Ward JR, Williams JH, and the Cooperative Systemic Studies of Rheumatic Diseases Group. Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. Arthritis Rheum 1990; 33: 477-84.
32. Elder RT, Xu Xl, Williams JW, Gong HH, Finnegan A, Chong ASF The immunosuppressive metabolite of leflunomide, A77 1726, affects murine T cells through two biochemical mechanisms. J Immunol. 159:1997;22-27.
33. Dimitrijevic M, Bartlett RR Leflunomide, a novel immunomodulating drug, inhibits homotypic adhesion of mononuclear cells in rheumatoid arthritis. Transplant Proc. 28:1996;3086-3087.
34. van Eden AE, Laan RFJM, Blom HJet al. Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity. Semin Arthritis Rheum. 27:1998;277-292.
35. Hannonnen P, Mottonen T, Hakola M, Oka M Sulphasalazine in early rheumatoid arthritis. Arthritis Rheum. 36:1993;1501-1509.
36. Pinals RS, Kaplan SB, Lawson JGet al. Sulfasalazine in rheumatoid arthritis: a 48-week double-blind, prospective, placebo-controlled study. Arthritis Rheum. 29:1986;1427-1434.
37. Weinblatt ME, Kremer JM, Coblyn JSet al. Combination therapy with leflunomide-methotrexate in refractory rheumatoid arthritis. Rheum Eur. 27(suppl 2):1998;S110.
38. van Leeuwen MA, van Rijswijk MH, Sluiter WJet al. Individual relationship between progression of radiological damage and the acute phase response in early rheumatoid arthritis: towards development of a decision support system. J Rheumatol. 24:1997;20-27.
39. van Gerstel AM, Prevoo MLL, van't Hof MA, van Rijswijk MH, van de Putte LBA, van Riel PLCM Development and validation of the European League against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the WHO/International League Against Rheumatism criteria. Arthritis Rheum. 39:1996;4-14.
40. Wells G, Tugwell P Cyclosporin A in rheumatoid arthritis: overview of efficacy. Br J Rheumatol. 32(suppl 1):1993;51-56.
41. Hamdy H, McKendry RJR, Mierins E, Liver JA Low-dose methotrexate compared with azathioprine in the treatment of rheumatoid arthritis: a twenty-four week controlled clinical trial. Arthritis Rheum. 30:1987;361-367.
42. Otterness IG The value of C-reactive protein measurement in rheumatoid arthritis. Semin Arthritis Rheum. 24:1994;91-104.
43. Rains CP, Noble SN, Faulds D Sulfasalazine: a review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis. Drugs. 50:1995;137-156.